Chemical genomics with natural products

Journal of Microbiology and Biotechnology

Volumn 16, Issue 5, 2006, Pages 651-660

  Jung, Hye Jin ^a   Kwon, Ho Jeong ^a  

^a Yonsei University   (South Korea)

Author keywords

Chemical genomics; Natural products; Target identification and validation

Indexed keywords

ADENOSYLHOMOCYSTEINASE INHIBITOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; APICIDIN; BENZOIC ACID DERIVATIVE; CALCINEURIN; COLCHICINE; CURCUMIN; CYCLOSPORIN A; DIDEMNIN B; DOXORUBICIN; FR 901228; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; HALICHONDRIN B; HYDRAZINOBENZOYLCURCUMIN; ILIMAQUINONE; LACTACYSTIN; NATURAL PRODUCT; OVALICIN; PACLITAXEL; PARTHENOLIDE; PATEAMINE A; RADICICOL; RAPAMYCIN; TACROLIMUS; THERMOZYMOCIDIN; TRAPOXIN B; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ASPERGILLUS FUMIGATUS; BONE MARROW TOXICITY; CANCER INHIBITION; CHEMICAL STRUCTURE; CLINICAL TRIAL; COLCHICUM; COLON CANCER; CURCUMA LONGA; DRUG APPROVAL; DRUG BINDING; DRUG DESIGN; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL GENOMICS; FUNGUS; GENETIC IDENTIFICATION; HUMAN; MARINE ENVIRONMENT; MICROORGANISM; NATURAL SELECTION; NONHUMAN; NUTRIGENOMICS; PHENOTYPE; PROTEIN TARGETING; REVIEW; STREPTOMYCES TSUKUBAENSIS; STRUCTURE ANALYSIS; T LYMPHOCYTE ACTIVATION; UNITED STATES; VALIDATION STUDY;

EID: 33744948627     PISSN: 10177825     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Abe, J., W. Zhou, N. Takuwa, J. Taguchi, K. Kurokawa, M. Kumada, and Y. Takuwa. 1994. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res. 54: 3407-3412.
2. Adam, G. C., C. D. Vanderwal, E. J. Sorensen, and B. F. Cravatt. 2003. (-)-FR182877 is a potent and selective inhibitor of carboxylesterase-1. Angew Chem. Int. Ed. Engl. 42: 5480-5484.
3. Altmann, K. H. 2001. Microtubule-stabilizing agents: A growing class of important anticancer drugs. Curr. Opin. Chem. Biol. 5: 424-431.
4. Arbiser, J. L., N. Klauber, R. Rohan, R. van Leeuwen, M. T. Huang, C. Fisher, E. Flynn, and H. R. Byers. 1998. Curcumin is an in vivo inhibitor of angiogenesis. Mol. Med. 4: 376-383.
5. Bae, M. A., K. Yamada, D. Uemura, J. H. Seu, and Y. H. Kim.1998. Aburatubolactam C, a novel apoptosis-inducing substance produced by marine Streptomyces sp. SCRC A-20. J. Microbiol. Biotechnol. 8: 455-460.
6. Bierer, B. E., P. K. Somers, T. J. Wandless, S. J. Burakoff, and S. L. Schreiber. 1990. Probing immunosuppressant action with a nonnatural immunophilin ligand. Science 250: 556-559.
7. Borel, J. F., C. Feurer, C. Magnee, and H. Stahelin. 1977. Effects of the new anti-lymphocyytc peptide cyclosporin A in animals. Immunology 32: 1017-1025.
8. Borisy, G. G. and E. W. Taylor. 1967. The mechanism of action of colchicine. Binding of colchicine-3H to cellular protein. J. Cell Biol. 34: 525-533.
9. Buchnicek, J. 1950. Colchicine in ripening seeds of the wild saffron (Colchicum autumnale L). Pharm. Acta Helv. 25: 389-401.
10. Butler, M. S. 2004. The role of natural product chemistry in drug discovery. J. Nat. Prod. 67: 2141-2153.
11. Butler, M. S. 2005. Natural products to drugs: Natural product derived compounds in clinical trials. Nat. Prod. Rep. 22: 162-195.
12. Chen, J. K., W. S. Lane, and S. L. Schreiber. 1999. The identification of myriocin-binding proteins. Chem. Biol. 6: 221-235.
13. Cheung, W. Y. 1980. Calmodulin plays a pivotal role in cellular regulation. Science 207: 19-27.
14. Clardy, J. and C. Walsh. 2004. Lessons from natural molecules. Nature 432: 829-837.
15. Clipstone, N. A. and G. R. Crabtree. 1992. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357: 695-697.
16. Crews, C. M., W. S. Lane, and S. L. Schreiber. 1996. Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis. Proc. Natl. Acad. Sci. USA 93: 4316-4319.
17. Fenteany, G., R. F. Standaert, W. S. Lane, S. Choi, E. J. Corey, and S. L. Schreiber. 1995. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 5: 726-731.
18. Fujii, H., M. Nakajima, I. Saiki, J. Yoneda, I. Azuma, and T. Tsuruo. 1995. Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin. Exp. Metastasis 13: 337-344.
19. Gingras, A. C., B. Raught, and N. Sonenberg. 1999. eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 68: 913-963.
20. Griffith, E. C., Z. Su, B. E. Turk, S. Chen, Y. H. Chang, Z. Wu, K. Biemann, and J. O. Liu. 1997. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. 4: 461-471.
21. Hait, W. N. 1987. Targeting calmodulin for the development of novel cancer chemotherapeutic agents. Anticancer Drug Des. 2: 139-149.
22. Handschumacher, R. E., M. W. Harding, J. Rice, R. J. Drugge, and D. W. Speicher. 1984. Cyclophilin: A specific cytosolic binding protein for cyclosporin A. Science 226: 544-547.
23. Harding, M. W., A. Galat, D. E. Uehling, and S. L. Schreiber. 1989. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 341: 758-760.
24. He, L., G. A. Orr, and S. B. Horwitz. 2001. Novel molecules that interact with microtubules and have functional activity similar to taxol. Drug Discov Today 6: 1153-1164.
25. Heitman, J., N. R. Movva, and M. N. Hall. 1991. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 23: 905-909.
26. Heitman, J., N. R. Movva, P. C. Hiestand, and M. N. Hall. 1991. FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 88: 1948-1952.
27. Hou, T. and X. Xu. 2004. Recent development and application of virtual screening in drug discovery: An overview. Curr. Pharm. Des. 10: 1011-1033.
28. Ingber, D., T. Fujita, S. Kishimoto, K. Sudo, T. Kanamaru, H. Brem, and J. Folkman. 1990. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348: 555-557.
29. Itazaki, H., K. Nagashima, K. Sugita, H. Yoshida, Y. Kawamura, Y. Yasuda, K. Matsumoto, K. Ishii, N. Uotani, and H. Nakai. 1990. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J. Antibiot. 43: 1524-1532.
30. Jin, Y., J. Yu, and Y. G. Yu. 2002. Identification of hNopp140 as a binding partner for doxorubicin with a phage display cloning method. Chem. Biol. 9: 157-162.
31. Jordan, M. A. and L. Wilson. 1998. Microtubules and actin filaments: Dynamic targets for cancer chemotherapy. Curr. Opin. Cell Biol. 10: 123-130.
32. Kelloff, G. J., J. A. Crowell, E. T. Hawk, V. E. Steele, R. A. Lubet, C. W. Boone, J. M. Covey, L. A. Doody, G. S. Omenn, and P. Greenwald. 1996. Strategy and planning for chemopreventive drug development: Clinical development plans II. J. Cell Biochem. 26: 54-71.
33. Kijima, M., M. Yoshida, K. Sugita, S. Horinouchi, and T. Beppu. 1993. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem. 268: 22429-22435.
34. Kim, H. J., J. H. Kim, C. H. Lee, and H. J. Kwon. 2006. Gentisyl alcohol, an antioxidant from microbial metabolite, induces angiogenesis in vitro. J. Microbiol. Biotechnol. 16: 475-479.
35. Kino, T., H. Hatanaka, S. Miyata, N. Inamura, M. Nishiyama, T. Yajima, T. Goto, M. Okuhara, M. Kohsaka, H. Aoki, and H. Imanaka. 1987. FK-506, a novel immunosuppressant isolated from a Streptomyces. J. Antibiot. 40: 1256-1265.
36. Ko, H. R. 2002. PC-766B' and PC-766B, 16-membered macrolide angiogenesis inhibitors produced by Nocardia sp. RK97-56. J. Microbiol. Biotechnol. 12: 829-833.
37. Koehn, F. E. and G. T. Carter. 2005. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 4: 206-220.
38. Kwok, B. H., B. Koh, M. I. Ndubuisi, M. Elofsson, and C. M. Crews. 2001. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem. Biol. 8: 759-766.
39. Kwon, H. J. 2003. Chemical genomics-based target identification and validation of anti-angiogenic agents. Curr. Med. Chem. 10: 717-736.
40. Kwon, H. J. 2006. Discovery of new small molecules and targets towards angiogenesis via chemical genomics approach. Curr. Drug Targets 7: 397-405.
41. Kwon, H. J., J. H. Kim, H. J. Jung, Y. G. Kwon, M. Y. Kim, J. R. Rho, and J. H. Shin. 2001. Anti-angiogenic activity of Acalycixenolide E, a novel marine natural product from Acalycigorgia inermis. J. Microbiol. Biotechnol. 11: 656-662.
42. Levine, M. 1951. The action of colchicine on cell division in human cancer, animal, and plant tissues. Ann. N. Y. Acad. Sci. 51: 1365-1408.
43. Liu, J., J. D. Jr. Farmer, W. S. Lane, J. Friedman, I. Weissman, and S. L. Schreiber. 1991. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807-815.
44. Liu, S., J. Widom, C. W. Kemp, C. M. Crews, and J. Clardy. 1998. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 282: 1324-1327.
45. Look, A. T., R. A. Ashmun, L. H. Shapiro, and S. C. Peiper. 1989. Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J. Clin. Invest. 83: 1299-1307.
46. Low, W. K., Y. Dang, T. Schreider-Poetsch, Z. Shi, N. S. Choi, W. C. Merrick, D. Romo, and J. O. Liu. 2005. Inhibition of eukaryotic translation initiation by the marine natural product pateamine A. Mol. Cell 20: 709-722.
47. Lowther, W. T., D. A. McMillen, A. M. Orville, and B. W. Matthews. 1998. The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase. Proc. Natl. Acad. Sci. USA 95: 12153-12157.
48. Luibrand, R. T., T. R. Erdman, J. J. Vollmer, P. J. Scheuer, J. Finer, and J. Clardy. 1979. Ilimaquinone, a sesquiterpenoid quinone from a marine sponge. Tetrahedron 35: 609-612.
49. Macarron, R. 2006. Critical review of the role of HTS in drug discovery. Drug Discov. Today 11: 277-279.
50. Meng, L., B. H. Kwok, N. Sin, and C. M. Crews. 1999. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res. 59: 2798-2801.
51. Mohri, H. 1968 Amino-acid composition of "Tubulin" constituting microtubules of sperm flagella. Nature 217: 1053-1054.
52. Newman, D. J., G. M. Cragg, and K. M. Snader. 2000. The influence of natural products upon drug discovery. Nat. Prod. Rep. 17: 215-234.
53. Newman, D. J., G. M. Cragg, and K. M. Snader. 2003. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 66: 1022-1037.
54. Nishi, K., M. Yoshida, D. Fujiwara, M. Nishiyama, S. Horinouchi, and T. Beppu. 1994. Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. J. Biol. Chem. 269: 6320-6324.
55. Northcote, P. T., J. W. Blunt, and M. H. G. Munro. 1991. Pateamine: A potent cytotoxin from the New Zealand marine sponge, Mycale sp. Tetrahedron Lett. 32: 6411-6414.
56. Osawa, M., M. B. Swindells, J. Tanikawa, T. Tanaka, T. Mase, T. Furuya, and M. Ikura. 1998. Solution structure of calmodulin-W-7 complex: The basis of diversity in molecular recognition. J. Mol. Biol. 276: 165-176.
57. Paterson, I. and E. A. Anderson. 2005. The renaissance of natural products as drug candidates. Science 21: 451-453.
58. Peterson, J. R. and T. J. Mitchison. 2002. Small molecules, big impact: A history of chemical inhibitors and the cytoskeleton. Chem. Biol. 9: 1275-1285.
59. Piggott, A. M. and P. Karuso. 2004. Quality, not quantity: The role of natural products and chemical proteomics in modern drug discovery. Comb. Chem. High Throughput Screen 7: 607-630.
60. Radeke, H. S., C. A. Digits, R. L. Casaubon, and M. L. Snapper. 1999. Interactions of (-)-ilimaquinone with methylation enzymes: Implications for vesicular-mediated secretion. Chem. Biol. 6: 639-647.
61. Radeke, H. S. and M. L. Snapper. 1998. Photoaffinity study of the cellular interactions of ilimaquinone. Bioorg. Med. Chem. 6: 1227-1232.
62. Rodeschini, V., J. G. Boiteau, P. Van de Weghe, C. Tarnus, and J. Eustache. 2004. MetAP-2 inhibitors based on the fumagillin structure. Side-chain modification and ring-substituted analogues. J. Org. Chem. 69: 357-373.
63. Rosato, R. R. and S. Grant. 2004. Histone deacetylase inhibitors in clinical development. Expert Opin. Investig. Drugs 13: 21-38.
64. Rozen, F., I. Edery, K. Meerovitch, T. E. Dever, W. C. Merrick, and N. Sonenberg. 1990. Bidirectional RNA helicase activity of eucaryotic translation initiation factors 4A and 4F. Mol. Cell Biol. 10: 1134-1144.
65. Ruegger, A., M. Kuhn, H. Lichti, H. R. Loosli, R. Huguenin, C. Quiquerez, and A. von Wartburg. 1976. Cyclosporin A, a peptide metabolite from Trichoderma polysporum Rifai, with a remarkable immunosuppressive activity. Helv. Chim. Acta 59: 1075-1092.
66. Saiki, I., H. Fujii, J. Yoneda, F. Abe, M. Nakajima, T. Tsuruo, and I. Azuma. 1993. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int. J. Cancer 54: 137-143.
67. Sato, Y. 2003. Aminopeptidases and angiogenesis. Endothelium 10: 287-290.
68. Sawada, S., G. Suzuki, Y. Kawase, and F. Takaku. 1987. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J. Immunol. 139: 1797-1803.
69. Schreiber, S. L. 1998. Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorg. Med. Chem. 6: 1127-1152.
70. Sharma, S. V., T. Agatsuma, and H. Nakano. 1998. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 16: 2639-2645.
71. Shim, J. S., D. H. Kim, H. J. Jung, J. H. Kim, D. Lim, S. K. Lee, K. W. Kim, J. W. Ahn, J. S. Yoo, J. R. Rho, and H. J. Kwon. 2002. Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. Bioorg. Med. Chem. 10: 2987-2992.
72. Shim, J. S. and H. J. Kwon. 2004. Chemical genetics for therapeutic target mining. Expert Opin. Ther. Targets 8: 653-661.
73. Shim, J. S., J. H. Kim, H. Y. Cho, Y. N. Yum, S. H. Kim, H. J. Park, B. S. Shim, S. H. Choi, and H. J. Kwon. 2003. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem. Biol. 10: 695-704.
74. Shim, J. S., J. Lee, H. J. Park, S. J. Park, and H. J. Kwon. 2004. A new curcumin derivative, HBC, interferes with the cell cycle progression of colon cancer cells via antagonization of the Ca2+/calmodulin function. Chem. Biol. 11: 1455-1463.
75. Siekierka, J. J., S. H. Hung, M. Poe, C. S. Lin, and N. H. Sigal. 1989. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 341: 755-757.
76. Sigg, H. P. and H. P. Weber. 1968. Isolation and structure elucidation of ovalicin. Helv. Chim. Acta 51: 1395-1408.
77. Sin, N., L. Meng, M. Q. Wang, J. J. Wen, W. G. Bornmann, and C. M. Crews. 1997. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. Natl. Acad. Sci. USA 94: 6099-6103.
78. Sternson, S. M., J. C. Wong, C. M. Grozinger, and S. L. Schreiber. 2001. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org. Lett. 3: 4239-4242.
79. Takizawa, P. A., J. K. Yucel, B. Veit, D. J. Faulkner, T. Deerinck, G. Soto, M. Ellisman, and V. Malhotra. 1993. Complete vesiculation of Golgi membranes and inhibition of protein transport by a novel sea sponge metabolite, ilimaquinone. Cell 73: 1079-1090.
80. Taunton, J., C. A. Hassig, and S. L. Schreiber. 1996. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272: 408-411.
81. Thaloor, D., A. K. Singh, G. S. Sidhu, P. V. Prasad, H. K. Kleinman, and R. K. Maheshwari. 1998. Inhibition of angiogenic differentiation of human umbilical vein endothelial cells by curcumin. Cell Growth Differ. 9: 305-312.
82. Tong, J. K., C. A. Hassig, G. R. Schnitzler, R. E. Kingston, and S. L. Schreiber. 1998. Chromatin deacetylation by an ATP-dependent nucleosome remodelling complex. Nature 395: 917-921.
83. Towbin, H., K. W. Bair, J. A. DeCaprio, M. J. Eck, S. Kim, F. R. Kinder, A. Morollo, D. R. Mueller, P. Schindler, H. K. Song, J. van Oostrum, R. W. Versace, H. Voshol, J. Wood, S. Zabludoff, and P. E. Phillips. 2003. Proteomics-based target identification: Bengamides as a new class of methionine aminopeptidase inhibitors. J. Biol. Chem. 278: 52964-52971.
84. Towle, M. J., K. A. Salvato, J. Budrow, B. F. Wels, G. Kuznetsov, K. K. Aalfs, S. Welsh, W. Zheng, B. M. Seletsk, M. H. Palme, G. J. Habgood, L. A. Singer, L. V. Dipietro, Y. Wang, J. J. Chen, D. A. Quincy, A. Davis, K. Yoshimatsu, Y. Kishi, M. J. Yu, and B. A. Littlefield. 2001. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61: 1013-1021.
85. Vandonselaar, M., R. A. Hickie, J. W. Quail, and L. T. Delbaere. 1994. Trifluoperazine-induced conformational change in Ca(2+)-calmodulin. Nat. Struct. Biol. 1: 795-801.
86. Veigl, M. L., T. C. Vanaman, and W. D. Sedwick. 1984. Calcium and calmodulin in cell growth and transformation. Biochim. Biophys. Acta 738: 21-48.
87. Weisenberg, R. C., G. G. Borisy, and E. W. Taylor. 1968. The colchicine-binding protein of mammalian brain and its relation to microtubules. Biochemistry 7: 4466-4479.
88. Wong, D. L., R. J. Hayashi, and R. D. Ciaranello. 1985. Regulation of biogenic amine methyltransferases by glucocorticoids via S-adenosylmethionine and its metabolizing enzymes, methionine adenosyltransferase and S-adenosylhomocysteine hydrolase. Brain Res. 330: 209-216.
89. Yoshida, M., M. Kijima, M. Akita, and T. Beppu. 1990. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265: 17174-17179.